Triamterene and Hydrochlorothiazide Capsules — Class III drug recall D-0160-2023
Terminated recall by Lannett Company Inc., reported 2023-01-25, distributed nationwide. Failed Impurity/Degradation Specifications
| Recall number | D-0160-2023 |
|---|---|
| Product type | Drug |
| Classification | Class III |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Lannett Company Inc., Seymour, IN, United States |
| Recall initiated | 2022-11-09 |
| Classified | 2023-01-16 |
| Reported by FDA | 2023-01-25 |
| Terminated | 2023-06-08 |
| Distributed | Nationwide (US) |
| Quantity | 5,640 bottles |
| Reason classes | specification failure |
| NDC | 00527-1632-10 |
| Lot numbers | 20256318A |
Product
Triamterene and Hydrochlorothiazide Capsules, USP (37.5 mg/25 mg), Rx Only, 1000 Capsules per bottle, Distributed by: Lannett Company, Inc., Philadelphia, PA 19136. NDC: 0527-1632-10
Reason for recall
Failed Impurity/Degradation Specifications
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0160-2023. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.